Not a very sexy number; however, with that kind of growth, 15%, each week, Vascepa would surpass Lovaza sales by November. Obviously the law of large numbers would interfere with adding 15% growth before then, but you get the picture. The freebies refilling are going to figure into the weekly picture from now. Also, I'm pretty sure all JZ has to do is pick up the phone and this is gone at $20. The fact that Vascepa, with ANCHOR and combo's with statins, is potentially a much more valuable property is what keeps this from being a takeover, the price is too high. So the market values it like a dog for a few months. It doesn't make any sense, but you likely will not ever find a better price than right now. Downside seems to be around $7, which would be more insanity. Wouldn't be surprised to see this take off without warning. It's a $20 stock masquerading as a broken issue.